FDA approves APP Pharmaceuticals' Indomethacin for Injection
Links shared publicly online about this topic.
- 1,295total visits
FDA approves APP Pharmaceuticals' Indomethacin for Injection
View full resource at news-medical.net
Tags: Drug, Pharma, FDA, NSAIDs, Indocin
Most Recently Shared on March 23, 2010 at 11:02 am By:
Oncology News: FDA approves APP Pharmaceuticals' Indomethacin for Injection: APP Pharmaceuticals, Inc., a wholly o... http://bit.ly/9zVSFd
Also Shared By:
APP Pharmaceuticals Announces Approval And Launch Of Clonidine Hydrochloride Injection
medicalnewstoday.com — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA)” View full resource at medicalnewstoday.com
Most Recently Shared on July 12, 2011 at 7:05 am By:
MNT Drug Approvals Health News
APP Pharmaceuticals Announces Approval And Launch Of Clonidine Hydrochloride Injection http://mnt.to/3Y8L #regulatory
FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Piperacillin and Tazobactam for Injection, the number one prescribed intravenous antibiotic in the U.S. APP will launch the product immediately.” View full resource at news-medical.net
Most Recently Shared on June 1, 2011 at 6:50 am By:
FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection: APP Pharmaceuticals, Inc., a wholly... http://bit.ly/jzwV5L
APP Pharmaceuticals Announces Approval And Launch Of Gemcitabine HCI For Injection, USP In 2 Gram Dosage Form
medicalnewstoday.com — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA)” View full resource at medicalnewstoday.com
Most Recently Shared on May 19, 2011 at 12:07 pm By:
MNT Drug Approvals Health News
APP Pharmaceuticals Announces Approval And Launch Of Gemcitabine HCI For Injection, USP In 2 Gram Dosage Form http://mnt.to/3W67 #regulatory
APP receives FDA marketing approval for Metoprolol Tartrate Injection
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Metoprolol Tartrate Injection, USP, and expects to launch the medication soon.” View full resource at news-medical.net
Most Recently Shared on October 30, 2010 at 6:10 am By:
News-Medical.Net Health News and Oncology
Oncology News: APP receives FDA marketing approval for Metoprolol Tartrate Injection: APP Pharmaceuticals, Inc., a... http://bit.ly/9lRkrQ
APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene-IV, which is marketed by Roche Laboratories, Inc.” View full resource at news-medical.net
Most Recently Shared on June 22, 2010 at 9:22 am By:
News-Medical.Net Health News and Oncology
Oncology News: APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP: APP Pharmaceuti... http://bit.ly/bse8Vr
APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.” View full resource at news-medical.net
Most Recently Shared on June 21, 2010 at 9:11 am By:
News-Medical.Net Health News and Oncology
Oncology News: APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP: APP Pharmaceutica... http://bit.ly/bI0bhA
APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.” View full resource at news-medical.net
Most Recently Shared on October 21, 2009 at 7:18 pm By:
Stroke News: APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection: APP Pharmaceuticals.. http://twurl.nl/jkufff
FDA approves APP Pharmaceuticals' Idarubicin HCI injection
news-medical.net — “APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.” View full resource at news-medical.net
Most Recently Shared on August 10, 2009 at 2:05 pm By:
News-Medical.Net Health News and Oncology
Oncology News: FDA approves APP Pharmaceuticals' Idarubicin HCI injection: APP Pharmaceuticals, In.. http://bit.ly/a1e52
Advertisement
News-Medical.Net
@NewsMedical
FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection: APP Pharmaceuticals, Inc., a wholly... http://bit.ly/jzwV5L
1 year ago...